Follicular lymphoma: emerging therapeutic strategies

References

• Ganti AK, Bociek RG, Bierman PJ, Enke CA, Vose JM, Armitage JO. Follicular lymphoma: expanding therapeutic options. Oncology19, 213–228 (2005).
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris, NL et al.WHO Classification of Tumours of Hamatopoietic and Lymphoid Tissues. International Agency for Research on Cancer, Lyon, France, 220–226 (2008).
   Google Scholar
• Staudt LM. A closer look at follicular lymphoma. N. Engl. J. Med.356, 741–742 (2007).
   PubMed Web of Science ®Google Scholar
• Solal-Céligny P, Roy P, Colombat P et al. Follicular lymphoma international prognostic index. Blood104, 1258–1265 (2004).
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J. Clin. Oncol.27, 4555–4562 (2009).
   PubMed Web of Science ®Google Scholar
• Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr. The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin. Hematol.25, 11–16 (1988).
   PubMed Web of Science ®Google Scholar
• Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol.15(3), 1110–1117 (1997).
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Smith P, Norton A et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet362, 516–522 (2003).
   PubMed Web of Science ®Google Scholar
• Horning S. Natural history of and therapy for indolent non-Hodgkin’s lymphoma. Semin. Oncol.20(Suppl. 5), 75–83 (1993).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J. Clin. Oncol.25, 7565–7573 (2005).
   Google Scholar
• Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J. Clin. Oncol.23, 5019–5026 (2005).
   PubMed Web of Science ®Google Scholar
• Liu Q, Fayad L, Cabanillas F et al. Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center. J. Clin. Oncol.24, 1582–1589 (2006).
   PubMed Web of Science ®Google Scholar
• Hiddeman W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood106(12), 3725–3732 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood105(4), 1417–1423 (2005).
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J. Clin. Oncol.26, 4579–4586 (2008).
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J. Clin. Oncol.25(15), 1986–1992 (2007).
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL 2000 study. Blood112(13), 4824–4831 (2008).
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Taylor MD, Cerhan JR et al. Follicular lymphoma in the United States: first report of the National LymphoCare Study. J. Clin. Oncol.27, 1202–1208 (2009).
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Eghbali H, Monfardini S et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin’s lymphoma. J. Clin. Oncol.24(10), 1590–1596 (2006).
   PubMed Web of Science ®Google Scholar
• Zinzani PL, Pulsoni A, Perrotti A et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J. Clin. Oncol.22(13), 2654–2661 (2004).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, Maschmeyer G et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized Phase III study of the StiL (Study Group Indolent Lymphomas, Germany), Presented at: 51st Annual American Society of Hematology Meeting. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Hochster HS, Weller E, Ryan T et al. Results of E1496: a Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). Presented at: 40th Annual American Society of Clinical Oncology Meeting. New Orleans, LA, USA, 5–8 June 2004.
   Google Scholar
• Press OW, Unger JM, Braziel RM et al. Phase II Trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J. Clin. Oncol.24(25), 4143–4149 (2008).
   Web of Science ®Google Scholar
• Morschhauser F, Radford J, Van Hoof A et al. Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J. Clin. Oncol.26(32), 5156–5164 (2008).
   PubMed Web of Science ®Google Scholar
• Goff L, Summers K, Iqbal S et al. Quantitative PCR analysis for Bcl-2/IgH in a Phase III Study of yttrium-90 ibritumomab tiuxetan as consolidation of first remission in patients with follicular lymphoma. J. Clin. Oncol.27(36), 6094–6100 (2009).
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J et al.131I–tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med.352, 441–449 (2005).
   PubMed Web of Science ®Google Scholar
• Chen MG, Prosnitz LR, Gonzalez-Serva A, Fischer DB. Results of radiotherapy in control of stage I and II non-Hodgkin’s lymphoma. Cancer43(4), 1245–1254 (1979).
   PubMed Web of Science ®Google Scholar
• Paryani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS. Analysis of non-Hodgkin’s lymphomas with nodular and favorable histologies, stages I and II. Cancer52(12), 2300–2307 (1983).
   PubMed Web of Science ®Google Scholar
• Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, Anderson L, Linch DC. Clinical stage 1 non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. Br. J. Cancer69(6), 1088–1093 (1994).
   PubMed Web of Science ®Google Scholar
• Guadagnolo BA, Sigui L, Neuberg D et al. Long-term outcome and mortality trends in early-stage, grad 1–2 follicular lymphoma treated with radiation therapy. Int. J. Radiat. Oncol. Biol. Phys.64(3), 928–934 (2006).
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Al-Batran SE, Kim S-Z et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J. Clin. Oncol.3, 3383–3389 (2005).
   Google Scholar
• Robinson KS, Williams ME, van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J. Clin. Oncol.26, 4473–4479 (2008).
   PubMed Web of Science ®Google Scholar
• Kahl BS, Bartlett NL, Leonard JP et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer116, 106–114 (2010).
   PubMed Web of Science ®Google Scholar
• Cheson BD, Wendtner C-M, Pieper A et al. Optimal use of bendamustine in chronic lymphocytic leukemia, non-hodgkin lymphomas, and multiple myeloma: treatment recommendations from an International Consensus Panel. Clin. Lymphoma Myeloma10, 21–27 (2010).
   Google Scholar
• De Bella N, Taetle R, Kolibaba K et al. Results of a Phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma. Blood115, 475–480 (2010).
   PubMed Web of Science ®Google Scholar
• O’Connor OA, Wright J, Moskowitz C et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J. Clin. Oncol.23, 676–684 (2005).
   PubMed Web of Science ®Google Scholar
• de Vos S, Goy A, Dakhil SR et al. Multicenter randomized Phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma. J. Clin. Oncol.27, 5023–5030 (2009).
   PubMed Web of Science ®Google Scholar
• Fowler N, Kahl BS, Rosen P et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: encouraging activity in the Phase 2 VERTICAL study. Presented at: 51st Annual American Society of Hematology Meeting. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Friedberg JW, Vose JM, Kelly JL et al. Bendamustine, bortezomib, and rituximab in patients relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma (NHL): a multicenter Phase II clinical trial. Presented at: 51st Annual American Society of Hematology Meeting, New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Witzig TE, Wiernik PH, Moore T et al. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin’s lymphoma. J. Clin. Oncol.27, 5404–5409 (2009).
   PubMed Web of Science ®Google Scholar
• van Oers MHJ, Klasa R, Marcus RE et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized Phase 3 intergroup trial. Blood108, 3295–3301 (2006).
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood104(6), 1793–1800 (2004).
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a Phase 1/2 trial. Blood111, 5486–5495 (2008).
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Fayad L, Delwail V et al. Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. Presented at: 51st Annual American Society of Hematology Meeting. New Orleans, LA, USA, 5–8 December 2009.
   Google Scholar
• Witzig TE, Gordon LI, Cabanillas F et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.20, 2453–2463 (2002).
   PubMed Web of Science ®Google Scholar
• Witzig TE, White CA, Wiseman GA et al: Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J. Clin. Oncol.17, 3793–3803 (1999).
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J. Clin. Oncol.23, 7565–7573 (2005).
   PubMed Web of Science ®Google Scholar
• Gyan E, Foussard C, Bertrand P et al. High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years. Blood113, 995–1001 (2009).
   PubMed Web of Science ®Google Scholar
• Lenz G, Dreyling M, Schiegnitz E et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma – results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Blood104, 2667–2674 (2004).
   PubMed Web of Science ®Google Scholar
• Ladetto M, De Marco F, Benedetti F et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood111, 4004–4013 (2008).
   PubMed Web of Science ®Google Scholar
• Schouten HS, Qian W, Kvaloy S et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin’s lymphoma: results from the randomized European CUP trial. J. Clin. Oncol.21, 3918–3927 (2003).
   PubMed Web of Science ®Google Scholar
• Rohatiner AZS, Nadler L, Davies AJ et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J. Clin. Oncol.25, 2554–2559 (2007).
   PubMed Web of Science ®Google Scholar
• Toze CL, Shepherd JD, Connors JM et al. Allogeneic bone marrow transplantation for low-grade lymphoma and chronic lymphocytic leukemia. Bone Marrow Transplant.25, 605–612 (2000).
   PubMed Web of Science ®Google Scholar
• Stein RS, Greer JP, Goodman S, Kallianpur A, Ahmed MS, Wolff SN. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Bone Marrow Transplant.23(3), 227–233 (1999).
   PubMed Web of Science ®Google Scholar
• van Besien K, Sobocinski K, Rowlings P et al. Allogeneic bone marrow transplantation for low grade lymphoma. Blood92, 1832–1836 (1998).
   PubMed Web of Science ®Google Scholar
• Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant.31(8), 667–678 (2003).
   PubMed Web of Science ®Google Scholar
• van Besien K. Allogeneic stem cell transplantation in follicular lymphoma: recent progress and controversy. Presented at: 51st Annual American Society of Hematology Meeting. New Orleans, LA, USA 5–8 December 2009.
   Google Scholar
• Hari P, Carreras J, Zhang M-J et al. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. Biol. Blood Marrow Transplant.14(2), 236–245 (2008).
   PubMed Web of Science ®Google Scholar
• Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood111, 446–452 (2008).
   PubMed Web of Science ®Google Scholar
• Rezvani AR, Storer B, Maris M et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin’s lymphoma. J. Clin. Oncol.26, 211–217 (2008).
   PubMed Web of Science ®Google Scholar
• Khouri IF, McLaughlin P,Saliba RM et al. Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab. Blood111, 5530–5536 (2008).
   PubMed Web of Science ®Google Scholar